Category: cardiovascular disease

Measuring Lipoprotein(a) in Clinical Practice to Reduce the Burden of Cardiovascular Disease? Still Work in Progress.

lipoprotein in clinical setting

A recent review suggested that the use of lipoprotein (Lp) (a) measurement in clinical practice may have clinical and economic benefits for patients, healthcare systems, and society as a whole. However, widespread adoption of Lp(a) measurement in the general population has been hindered by limited treatment options targeting Lp(a) reduction. Cardiovascular disease (CVD) remains the Read More >

Posted on by Jeffery Osei, Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia; Laurence S. Sperling, Million Hearts initiative, Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, and Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta Georgia; Ijeoma Isiadinso, Emory Center for Heart Disease Prevention, Division of Cardiology, Emory University School of Medicine, Atlanta Georgia; Ridgely Fisk Green, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta Georgia3 CommentsTags ,

Saving a Million Hearts: One Heart at a Time!

Million Hearts® logo

Cardiovascular disease (CVD), principally ischemic heart disease and stroke, remains the leading cause of U.S. deaths for men and women and all races and ethnicities in spite of major progress in its prevention and treatment. CVD is also the greatest contributor to racial disparities in life expectancy. In 2012, 120 public and private partners and Read More >

Posted on by Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention and George A. Mensah, Center for Translation Research and Implementation Science, National Heart, Lung and Blood InstituteTags , , ,